Edition:
United States

CTi Biopharma Corp (CTIC.OQ)

CTIC.OQ on NASDAQ Stock Exchange Capital Market

0.36USD
22 Jul 2016
Change (% chg)

-- (--)
Prev Close
$0.36
Open
--
Day's High
--
Day's Low
--
Volume
200
Avg. Vol
344,888
52-wk High
$1.98
52-wk Low
$0.25

CTIC.OQ

Chart for CTIC.OQ

About

CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for... (more)

Overall

Beta: 1.21
Market Cap(Mil.): $100.91
Shares Outstanding(Mil.): 282.81
Dividend: --
Yield (%): --

Financials

  CTIC.OQ Industry Sector
P/E (TTM): -- 39.80 37.05
EPS (TTM): -0.49 -- --
ROI: -156.93 -5.86 14.35
ROE: -234.50 -4.70 15.56

BRIEF-CTI Biopharma Q1 earnings per share $0.01

* Q1 revenue $36.5 million versus $2.7 million Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

May 10 2016

FDA puts full clinical hold on CTI BioPharma's blood cancer drug

CTI BioPharma Corp said the U.S Food and Drug Administration has put a full clinical hold on the company's investigational new drug application for pacritinib.

Feb 09 2016

FDA puts full clinical hold on CTI BioPharma's blood cancer drug

Feb 9 CTI BioPharma Corp said the U.S Food and Drug Administration has put a full clinical hold on the company's investigational new drug application for pacritinib.

Feb 09 2016

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : New Constructs, LLC
$25.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : S&P Capital IQ Quantitative Report
$104.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.